Description

Ro 106-9920 is a potent inhibitor of NF-kappaB. Ro 106-9920 has the potential for the research of tumor and cancer diseases[1].–20°C, 3 years; 4°C, 2 years (Powder)–Cancer-programmed cell death–C10H7N5OS—-[1]Malaver E, et al. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost. 2009;7(8):1333-1343.–62645-28-7–245.26–99.0–O=S(C1=CC=CC=C1)C2=NN3N=NN=C3C=C2–Cancer–10 mM in DMSO–NF-κB—-NF-κB–Peptides